Table S4. Scoring of 83 included studies according to REMARK.

		Marker description	Patient characteristics	Information about treatment	Biological material &	Assay method	Sample selection & follow-up	Clinical endpoint definition	Variables included in analysis	Rational for sample size	Specification of statistical	Handling of marker values	Description of flow of patients	Basic demographic	Relation marker to standard	Univariable analysis	Multivariable analysis	Marker & standard variables	Further investigations (eg	Interpretations of results &	Implications for further	Score
REMARK item		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	SCORE
Marker	Study																					
ADAP1, BARHL2, CABLES2, DOT1L, ERAS, ESRRG, RNF220, ST6GALNAC5, TAF4, SLC20A2	Gaedcke et al. 2014	1	1	1	1	0.5	0.5	1	0.5	0	0.5	0	0.5	1	0	1	0	0	0.5	1	1	12
AOX-1, RARB2, RERG, ADAMTS9, IRF4, FOXE-1	Luo et al. 2016	1	1	0	1	1	0.5	1	0	0	1	0.5	0	1	0	1	1	0	0	1	0.5	11.5
Apaf-1, BCL2, p53	Benard et al. 2015	1	1	1	1	1	1	0.5	0	0.5	0.5	0	0.5	1	1	1	1	0.5	1	0.5	0.5	14.5
APC, MGMT	Chen et al. 2009	1	0.5	1	0.5	0.5	0.5	0.5	0	0	0.5	0	0.5	1	0	0	1	0	0	0.5	0.5	8.5
ASCL2, APCDD1, AXIN2, DKK1, LGR5	De Sousa et al. 2011	0.5	0.5	0	0	0.5	0.5	0	0	0	0.5	0	0.5	0.5	0	0.5	0	0	0.5	0.5	0.5	5.5
AXIN2, DKK1, APCDD1, ASCL2	Kandimalla et	1	1	1	1	1	0	1	1	0	0	0	0	1	0	1	1	0	1	1	1	15

	al. 2017					.5				.5	.5						.5						
BMP6	Sangplod et al. 2014	1	0.5	0	1	1	0.5	0.5	0	0	0	0	0	0	0.5	1	0	0	0	0	0.5	0.5	7
BNIP3	Shimizu et al. 2010	1	0.5	1	1	1	0	0	0	0	0.5	0	0.5	0	0.5	1	1	0	0	0.5	0	0	9
CD109, EVL, FLNC, NRCAM, IGFBP3	Yi et al. 2011	0.5	0.5	1	1	1	1	0	0	0	0.5	0	0.5	1	0.5	0.5	0.5	0.5	1	0.5	0.5	0	11
CDH13, FLBN3, DLEC1, hMLH1, RUNX3	Wang et al. 2012	1	0.5	1	1	1	1	0	0	0	0.5	0	0.5	0.5	0.5	0.5	0.5	0	1	0	0.5	0	10
CDKN2A (p16)	Liang et al. 1999	1	1	1	1	1	1	0	0	0	0.5	0	0.5	0.5	0.5	0.5	0	0	0	0	0.5	0.5	9.5
CDKN2A (p16)	Esteller et al. 2009	1	1	0.5	0.5	0.5	1	0	0	0.5	0.5	0	0.5	0.5	0	0.5	0.5	0	0	0	0.5	0.5	9
CDKN2A (p16)	Maeda et al. 2003	1	0	0	0.5	0.5	0.5	0	0	0	0.5	0	0.5	0.5	0.5	0.5	0	0	0	0	0	0.5	6.5
CDKN2A (p16)	Sanz-Casla et al. 2005	1	1	1	1	1	1	0	0	0	0.5	0	0.5	0.5	0.5	0.5	0	0	0	0	0.5	0.5	9.5
CDKN2A (p16)	Nakayama et al. 2007	1	0	0	0.5	1	0	0	0	0	0.5	0	0.5	1	1	1	0	0	0	0.5	0	0	7
CDKN2A (p16)	Wettergren et al. 2008	1	0.5	1	1	1	0.5	1	0	0.5	0.5	0	0.5	1	1	0.5	1	0	0	0.5	0	0	11.5
CDKN2A (p16)	Wettergren et	1	1	0	0	0	1	1	0	0	0	0	0	1	0	1	1	0	0	0	0	0	11

	al. 2010			.5	.5	.5					.5		.5					.5		.5	.5	
CDKN2A (p16)	Malhotra et al. 2010	1	0.5	0.5	1	0.5	1	0.5	0	0	0.5	0	0	0	0	1	0	0	0	1	0	7.5
CDKN2A (p16)	Mitomi et al. 2009	1	1	1	1	1	0.5	1	0	0.5	0.5	0	0.5	0.5	1	1	1	1	0	0.5	0.5	13.5
CDKN2A (p16)	Shima et al. 2011	1	0.5	0.5	1	0.5	1	1	1	0	1	0	0.5	1	1	1	1	1	1	1	1	16
CDKN2A (p16)	Bihl et al. 2012	1	0.5	0	0.5	0.5	0.5	0	0	0	0.5	0	0.5	0.5	1	0.5	1	1	0	0.5	0.5	9
CDKN2A (p16)	Veganzones-de-Castro et al. 2012	1	1	1	1	1	0.5	1	0	0.5	0.5	0	0.5	1	1	1	0	0.5	0	0.5	0.5	12.5
CDKN2A (p16)	Kohonen-Corish et al. 2014	1	1	0.5	1	0.5	1	1	0	0	0.5	0	0.5	1	0	1	1	0.5	0	1	0.5	12
CDKN2A (p16), p15	Ishiguro et al. 2006	1	0.5	0	1	1	0	1	0	0	0.5	0	0	1	1	0	0	0	0	1	1	9
CDKN2A (p16), hMLH1	Aoyagi et al. 2011	1	1	1	1	0.5	0.5	0	0	0	0.5	0	0.5	1	1	1	0	0	0	0.5	0.5	10
CDKN2A (p16), hMLH1	Miladi-Abdennadher et al. 2011	1	0.5	1	1	1	0.5	0.5	0	0	0.5	0	0.5	1	1	1	1	0	0	1	0.5	12
CDKN2A (p16), BNIP3, hMLH1	Iida et al. 2012	1	1	1	1	1	1	0	0	0	0.5	0	0.5	0	0	0	1	1	0	0.5	0.5	11.5
CDKN2A (p16), hMLH1	Veganzones et	1	1	1	1	0	0	1	0	0	0	0	0	1	1	1	0	0	0	1	0	12

	al. 2015				.5	.5		.5		.5		.5								.5	
CDKN2A (p16), MGMT	Krtolica et al. 2007	1	0.5	1	1	1	0.5	0	0	0	0.5	0	0.5	0	1	1	0	0	0	0.5	0.5	9.5
CDKN2A (p16), APC, CDH1, MGMT	Kamiyama et al. 2009	0.5	0.5	1	1	1	0.5	0	0	0.5	0.5	0	0.5	0	1	0.5	0	0	0	0.5	0.5	8.5
CDKN2A (p16), hMLH1, MGMT	Kuan et al. 2015	1	0.5	0	0	1	0.5	1	1	0	0.5	0	0.5	1	0	0.5	0	0	0	1	0.5	11
CDKN2A (p16), IGFBP7, KLOTHO, hMLH1,PHD3, SFRP2	Yang et al. 2014	1	0.5	0	1	1	0	0	1	0	0.5	0	0.5	1	1	0	1	0.5	0	0.5	0.5	10.5
CDX2	Jiang et al. 2016	1	1	0.5	0	1	0.5	0	0	0	0.5	0	0.5	0	1	0.5	1	0	0	0.5	0.5	9.5
CHFR, ID4, RECK, MINT1	Tanaka et al. 2011	1	1	0.5	1	1	0.5	0	1	1	0.5	0	0.5	0	1	0	1	1	0.5	1	1	14.5
CHFR, PLOD1, CDKN2A (p16), CDKN2A (p14ARF), MGMT, RASSF1, APC, HLTF, GATA4, GATA5, ADAM23, RAB32, JPH3, FOXL2, BNIP3, NEURL1, CACNA2, THBS1, TFPI2	Cleven et al. 2014	1	1	1	1	1	1	1	1	0.5	0.5	0	0.5	1	1	1	1	1	1	1	1	17.5
DACT2	Wang et al. 2015	1	0.5	0	0	0.5	0	0	0	0	0.5	0	0.5	0	0	0.5	1	0	0	0.5	0.5	7
DSC3	Cui et al. 2011	1	0.5	1	0.5	1	0	0	0	0	0.5	0	0.5	0.5	0.5	0.5	0	0	0.5	0.5	0.5	8
EPAS1	Rawlusko-Wieczorek et al. 2014	1	1	1	1	1	0.5	1	0	1	0.5	0	0.5	1	0	0	1	0.5	0	0.5	0.5	12
FBLN1	Xu et al. 2015	1	0	0	0	1	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	9.

			.5	.5	.5		.5		.5		.5					.5		.5		.5		5
HLTF, HPP1, hMLH1	Wallner et al. 2006	1	0	0	1	1	1	1	1	1	0	0	0	1	1	1	1	1	0	0	0	15
			.5	.5							.5		.5							.5	.5	
HLTF, HPP1	Herbst et al. 2009	1	0	0	1	1	1	1	1	1	0	0	0	1	1	1	1	1	0	0	0	14
			.5								.5		.5							.5	.5	.5
HLTF, HPP1	Philipp et al. 2012	1	0	1	1	1	0	1	0	1	0	0	0	1	1	0	0	0	0	0	1	12
											.5		.5			.5	.5	.5	.5	.5		.5
HLTF, HPP1	Philipp et al. 2014	1	0	1	1	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	10
			.5					.5			.5		.5			.5	.5			.5	.5	
HPP1	Herbst et al. 2017	1	1	1	1	1	0	1	0	0	1	1	0	1	0	1	0	0	0	1	1	15
							.5			.5			.5				.5	.5	.5			
hMLH1	Jensen et al. 2013	1	0	0	1	1	0	1	1	0	0	0	0	1	0	1	0	0	0	1	1	11
			.5								.5		.5						.5			
hMLH1	Wang et al. 2014	1	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	1	0	10
			.5	.5		.5		.5			.5		.5				.5				.5	
hMLH1, hMSH2	Malhotra et al. 2014	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6.
			.5	.5			.5	.5			.5									.5	.5	5
HOPX	Katoh et al. 2012	1	0	0	0	1	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	9.
			.5		.5		.5				.5		.5		.5			.5		.5	.5	5
ID4	Umetani et al. 2004	1	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	9.
			.5		.5		.5			.5	.5		.5							.5		5
IGFBP3	Fu et al. 2015	1	0	0	1	1	1	0	0	0	0	0	0	1	1	1	1	1	1	1	1	14

			.5	.5							.5		.5									
IGFBP3, ALX4, GAS7	Perez-Carbonell et al. 2014	1	1	0.5	0.5	1	0.5	1	1	0	0.5	0	0	1	1	1	1	1	0	1	0.5	13.5
IGF2	Baba et al. 2010	1	0.5	0.5	1	1	1	1	1	0.5	1	0.5	0.5	1	1	1	1	1	0.5	1	1	17
KISS-1	Moya et al. 2013	1	0	0	1	0.5	0	1	0	0	0.5	0	0.5	1	0	0.5	0	0	1	0.5	0.5	9
LGR5	Su et al. 2015	1	1	1	0.5	1	0.5	0	0.5	0	0.5	0	0	1	0.5	0	0	0	0.5	0.5	0.5	9
MGMT	Shima et al. 2011	1	0.5	0.5	1	0.5	1	1	1	0.5	0.5	0.5	0.5	1	1	1	1	0.5	1	1	1	16
MGMT	Oliver et al. 2014	1	1	1	1	1	1	0.5	0.5	0	0.5	0	0.5	1	0	1	0.5	0.5	0	0.5	0.5	12
MYOD1 (Myf-3)	Shannon et al. 1999	1	0	0	0.5	0.5	0	0.5	0	0	0.5	0	0	0	0.5	0.5	0	0	0	0.5	0	4.5
MYOD1	Hiranuma et al. 2004	1	0.5	0	1	1	0.5	0	0	0	0.5	0	0.5	1	1	0	1	0	0	0.5	0.5	9
SYNPO2 (Myopodin)	Esteban et al. 2012	1	0	0	1	0.5	0	1	1	0	0.5	0	0.5	0.5	1	0.5	0	0	1	0.5	1	10
CDKN2A (p14/ARF)	Chaar et al. 2014	1	0.5	0	1	1	0	0	0	0	0.5	0	0.5	0.5	1	1	0	0	0	0.5	0.5	8
PCDH10, SPARC, UCHL1, UCHL2, UCHL3, FZD9, SFRP1, WIF1	Heitzer et al.	1	0	1	1	1	1	1	1	0	0	0	1	0	1	1	0	0	0	0.5	1	14

	2014		.5						.5	.5			.5					.5	.5			
PPARG	Pancione et al. 2010	1	0.5	1	1	1	1	0	0	0	0	0	0	1	1	1	0	0	0.5	0	0.5	11
PTEN	Lin et al. 2015	1	0.5	1	1	1	1	1	0	0	0.5	0	0	1	1	1	1	0	0.5	0	0.5	13.5
RARß2, RASSF1, CDH1, DABK1	Miladi-Abdennadher et al. 2010	1	0.5	1	0	1	0.5	0	0	0.5	0.5	0	0.5	0.5	1	1	0.5	0.5	0	1	0.5	11
RASSF1 (RASSF1A)	Chen et al. 2012	1	0.5	1	0	1	0.5	0.5	0	0	0.5	0	0.5	1	0	1	1	0	0	0.5	0.5	10
RASSF1 (RASSF1A), CDKN2A (p14/ARF), APC1A	Nilsson et al. 2013	1	0	0	0	0.5	0	0	0	0	0.5	0	0.5	0	0	0.5	0	0	0	0.5	0.5	5
RASSF1 (RASSF1A), APC	Matthaios et al. 2016	1	0.5	0	1	1	0.5	0.5	0	0	0.5	0.5	0	1	1	0.5	0.5	0	0	0.5	0.5	9.5
RET	Draht et al. 2014	1	1	1	1	1	0.5	1	1	0	0.5	0	0.5	0	1	1	1	0.5	1	1	1	15.5
TAC1, SEPT9, NELL1	Tham et al. 2015	1	1	1	1	0.5	1	1	0	0	0.5	0	0.5	1	0	1	1	1	1	1	1	14.5
TAC1, SEPT9, NELL1, EYA4, CRABP1, MAL, SST	Liu et al. 2016	1	1	1	1	0.5	1	1	0	0.5	0.5	0.5	0.5	1	0	1	1	0.5	0.5	1	1	15
SFRP1, SLIT2, HIC1, MYOD1, RASSF1, APC, MGMT	Dallol et al. 2012	1	0.5	0	1	1	0.5	1	0	0.5	0.5	0	0.5	1	0.5	1	0.5	0	0	0.5	0	10
SFRP2	Tang et al.	1	0	1	1	0	0	0	0	0	0	0	0	1	1	0	1	1	0	0	0	10

	2011		.5			.5				.5			.5							.5	.5	
SHISA3	Tsai et al. 2015	1	0	1	1	0	1	1	1	1	0	0	0	1	1	0	0	0	0	0	0	13
SLFN11	He et al. 2017	1	.5 0	0	0	.5 1	0	0	0	0	.5 0	0	.5 0	1	1	.5 1	.5 1	.5 0	0	.5 0	0	10
SOCS-1	Kang et al. 2016	1	.5 0	1	.5 1	0	.5 0	.5 0	0	0	.5 0	.5 0	0	1	1	.5 0	0	.5 0	0	.5 0	.5 0	.5 8. 5
SYK (Syk)	Yang et al. 2013	1	0	0	.5 0	1	0	1	0	0	.5 0	0	.5 0	0	1	.5 0	1	0	0	.5 0	0	7. 5
TBX5	Yu et al. 2010	1	0	0	.5 0	1	0	0	0	.5 0	.5 0	0	.5 0	0	1	1	1	1	0	.5 0	.5 0	9
TFAP2E	Zhang et al. 2014	1	.5 0	.5 0	1	1	0	.5 0	0	0	.5 0	0	.5 0	1	1	1	.5 0	0	0	1	.5 0	10 .5
TFAP2E	Park et al. 2015	1	1	1	.5 0	.5 0	.5 0	1	1	0	.5 0	0	.5 0	1	1	1	1	.5 0	.5 0	1	.5 0	14
TFAP2E	Beggs et al. 2015	1	0	0	0	.5 0	0	.5 0	.5 0	0	.5 0	0	0	0	0	1	0	0	0	.5 0	.5 0	5
TWIST1	Ruppenthal et al. 2011	1	.5 0	.5 0	1	1	.5 0	1	0	0	.5 0	0	.5 0	1	1	0	0	0	0	.5 0	.5 0	9. 5
WIF-1	Abdelmaksoud-Dammak et al. 2014	1	1	1	1	1	0	0	0	0	.5 0	0	0	1	1	1	0	0	0	.5 0	0	9
Wnt5a	Rawson et al.	1	0	0	1	1	1	1	0	0	0	0	0	1	1	0	1	0	1	0	0	12

	2011	. 5		. 5	. 5		. 5	. 5	. 5	. 5	.5